![\"\"](\"http:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2020\/10\/Screen-Shot-2020-10-12-at-6.16.37-AM.png\")
<\/a><\/p>\n\n
A total of 13 companies have gone public thus far in October — nine have been from the healthcare sector. Here’s a look at the IPOs that will debut in the upcoming calendar week.<\/p>\n
Debuting Wednesday (10\/14)<\/strong><\/span><\/p>\n Codiak BioSciences, Inc. (CDAK)<\/strong> — They are a development-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need.<\/p>\n Debuting Thursday (10\/15)<\/strong><\/span><\/p>\n Array Technologies, Inc. (ARRY)<\/strong> — They are one of the world\u2019s largest manufacturers of ground-mounting systems used in solar energy projects.<\/p>\n MINISO Group Holding Limited (MNSO)<\/strong> — They are a fast-growing global value retailer offering a variety of design-led lifestyle products.<\/p>\n Spinal Elements Holdings, Inc.(SPEL)<\/strong> — They are a medical device company focused on the design, development and commercialization of a comprehensive portfolio of systems, products and technologies for spine surgery procedures, with a strategic focus on minimally invasive surgery (\u201cMIS\u201d) procedures.<\/p>\n Debuting Friday (10\/16)<\/strong><\/span><\/p>\n Aligos Therapeutics, Inc. (ALGS) —<\/b> They are a clinical-stage biopharmaceutical company currently focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases.<\/p>\n Eargo, Inc (EAR) —<\/b> \u00a0They are a medical device company dedicated to improving the quality of life of people with hearing loss.<\/p>\n Opthea Limited (OPT) — <\/b>They are a clinical stage biopharmaceutical company developing a novel therapy for the treatment of highly prevalent and progressive retinal diseases.<\/p>\n Praxis Precision Medicines, Inc.(PRAX)<\/strong> — They are a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal imbalance.<\/p>\n Tarsus Pharmaceuticals, Inc. (TARS) —<\/b> They are a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities initially in ophthalmic conditions where there are limited treatment alternatives.<\/p>\n
\n